ABBOTT INDIA LTD Ltd. (NSE: ABBOTTINDIA): Q3 FY23 Results Out; Total Income Rises 10% YoY

Abbott India Limited (NSE:ABBOTTINDIA) is a subsidiary of Abbott Laboratories, a multinational healthcare company. It was established in India in 1944 and is headquartered in Mumbai. The company operates in the pharmaceutical and medical devices industries, offering a wide range of products, including prescription medicines, diagnostic equipment, and nutritional products. Abbott India is committed to improving the health and well-being of people in India, and has been actively involved in various initiatives to enhance healthcare in the country. The company has a strong presence in the Indian market and has a reputation for delivering high-quality products and services.

The company has recently reported its financial results for the December 2022 quarter, compared to the same quarter in the previous year and the September 2022 quarter.

In December 2022, the company’s sales increased to INR 1,326 crore, compared to INR 1,224 crore in December 2021, representing a growth of 8.39%. The company’s expenses increased to INR 1,010 crore in December 2022, compared to INR 955 crore in December 2021, reflecting an increase of 6.06%. As a result, Abbott India’s operating profit increased to INR 316 crore in December 2022, compared to INR 269 crore in December 2021, representing a growth of 17.24%. The operating profit margin increased from 22% in December 2021 to 24% in December 2022.

Abbott India’s net profit increased to INR 247 crore in December 2022, compared to INR 199 crore in December 2021, representing a growth of 24.12%. The company’s earnings per share (EPS) increased from INR 93.74 in December 2021 to INR 116.16 in December 2022, reflecting a growth of 24.13%.